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Background: Neoadjuvant chemotherapy has been shown to have benefit in T1 high-grade or T2 bladder cancer.
However, neoadjuvant chemotherapy fails in some patients. Careful patient selection for neoadjuvant chemotherapy is
therefore needed. Several reports show that Snail is associated with resistance to chemotherapy. We hypothesized that
Snail expression could predict survival in T1 high-grade and T2 bladder cancer patients treated with neoadjuvant
chemotherapy.
Methods: The participants were 44 patients with T1 high-grade and T2 bladder cancer receiving neoadjuvant
chemotherapy. Immunohistochemical analysis was used to determine Snail expression in specimens of bladder
cancer obtained by transurethral resection before neoadjuvant chemotherapy. The relationships between Snail
expression and patients’ outcomes were analyzed.
Results: Snail expression was positive in 15 of the 44 patients (34.1%) and negative in 29 (65.9%). Disease-free
survival was significantly shorter for the Snail-positive group than for the Snail-negative group (p = 0.014). In addition,
disease-specific survival was also significantly shorter for the Snail-positive group than for the Snail-negative group
(p = 0.039). In multivariate analysis, Snail expression level was identified as an independent prognostic factor for
disease-specific survival (p = 0.020).
Conclusions: The results indicate that Snail expression may predict poor outcome in T1 high-grade and T2 bladder
cancer patients treated with neoadjuvant chemotherapy.
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Bladder cancer is the ninth most common cancer diag-
nosis worldwide, with more than 130,000 deaths per year
[1]. Despite undergoing radical cystectomy in muscle-
invasive bladder cancer, 50% of patients die within 5 years
[2-6]. Clinical trials have tested the ability of neoadjuvant
chemotherapy to improve survival in muscle-invasive
bladder cancer. A meta-analysis of 11 trials involving 3005
patients demonstrated an absolute benefit of 5% in 5-year
overall survival among patients who were treated with
platinum-based neoadjuvant chemotherapy [7]. Several* Correspondence: shun1982@nms.ac.jp
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stated.other randomized studies have confirmed the benefit of
neoadjuvant chemotherapy in muscle-invasive bladder
cancer [8,9].
However, neoadjuvant chemotherapy has only a modest
effect in prolonging survival. We have attempted cisplatin-
based intra-arterial chemotherapy to increase local drug
concentrations instead of intravenous chemotherapy for
T1 high-grade and T2 bladder cancer. Our results have
shown a 5-year overall survival rate of 64.5%. In addition,
we reported that CYFRA 21-1 may be a useful indicator
for monitoring neoadjuvant chemotherapy [10]. However,
this marker could not predict the efficacy of neoadjuvant
chemotherapy before the fact, and neoadjuvant chemother-
apy fails in some patients. Patient selection should thus be
improved for neoadjuvant chemotherapy. Novel markersl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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patients are needed.
Epithelial-mesenchymal transition (EMT) is a process
initially observed in embryonic development in which
cells lose epithelial characteristics and gain mesenchymal
properties to increase motility and invasion [11]. Recent
research suggests that EMT is an important factor related
to tumor progression and metastasis [11,12]. EMT is
also associated with resistance to chemotherapy [13,14].
Furthermore, a recent study reported that Snail is a key
regulator of EMT [15]. Snail is a super family of zinc-
finger transcription factors, which was first identified
in Drosophila melanogaster [16]. Snail induces EMT, in
part, by directly repressing epithelial markers such as
E-cadherin and by upregulating mesenchymal markers.
Thus, Snail may be associated with tumor progression,
metastasis, and resistance to chemotherapy.
This finding led us to hypothesize that Snail could be a
predictor of resistance to cisplatin-based chemotherapy.
The present study therefore examined the association
between Snail expression and survival in T1 high-grade
and T2 bladder cancer patients treated with neoadjuvant
chemotherapy.Methods
Patients and samples
The cohort under investigation included 44 patients who
underwent neoadjuvant chemotherapy for pT1 high-grade
or pT2N0M0 bladder cancer at our institution between
October 2002 and February 2011. Having been compiled
for research purposes, this group represents patients for
whom pretreatment archival paraffin-embedded tissue
blocks and data from complete clinical follow-up were
available. Diagnostic work-up included initial transurethral
resection of bladder tumor (TURBT), pelvic magnetic
resonance imaging (MRI), chest and abdominal computed
tomography (CT), and bone scintigraphy. Tumors were
graded histologically in accordance with the World Health
Organization (WHO) classification and were staged as per
the TNM staging system of the Union for International
Cancer Control (2009).
Neoadjuvant intra-arterial chemotherapy was performed
after complete TURBT, only after the patient consented to
therapy based on our recommendation. Written informed
consent was obtained from all patients. Anticancer agents
administered as neoadjuvant chemotherapy consisted
of cisplatin 100 mg/m2, methotrexate 30 mg/m2, and
doxorubicin 20 mg/m2 of body surface area. The thera-
peutic protocol comprised two courses of neoadjuvant
chemotherapy. Following this, a second TURBT was
performed to obtain a biopsy specimen. In cases of super-
ficial or undetectable tumors on the second TURBT, the
bladder was preserved, while advanced cases and thosewith residual invasive bladder tumors were treated by total
cystectomy or systemic chemotherapy.
After the second TURBT, cystoscopy and urinary
cytological examination were performed every 3 months
for 2 years, every 6 months from 3 to 5 years, and annually
thereafter. Chest radiography and pelvic CT were performed
every 6 months for 3 years, and annually thereafter. In
cases with visible tumors or hyperemic mucosa in the
bladder on cystoscopy or pelvic urinary cytological
findings, transurethral biopsy was performed to detect
disease recurrence.
This study was carried out in accordance with the
Declaration of Helsinki and Good Clinical Practice Guide-
lines. Approval of the protocol was obtained from the
Institutional Review Board of Nippon Medical School.
Immunohistochemistry
Snail expression was determined by immunohistochemical
staining of paraffin-embedded tissue sections from TURBT
specimens just before neoadjuvant chemotherapy. The
3-μm-thick sections were deparaffinized, rehydrated using
xylene and alcohol, and incubated with 0.3% H2O2 to block
endogenous peroxidase activity. Before immunostaining,
antigen was retrieved at 120°C for 15 min in an autoclave
with citrate buffer (pH 6.0). Staining with polyclonal
anti-Snail antibody (ab63371; Abcam, Cambridge, MA,
USA) with diluents, 1:100, was performed overnight at 4°C.
Histofine Simple Stain Rabbit MAX PO (MULTI; Nichirei,
Tokyo, Japan) was used as the second antibody in ac-
cordance with the manufacturer’s instructions. Color
was developed using diaminobenzidine with 0.01% H2O2.
Hematoxylin was used as a counterstain.
The stained tumor tissues were evaluated blindly with
respect to clinical patient data. Nuclear staining was con-
sidered positive. Staining intensity was scored as 0, 1, 2, or
3, which corresponded to no staining, weak, moderate,
and strong intensities (Figure 1), respectively. Percentage
scores of nuclear stained cells were also counted (0-100%).
Total histochemical score (H-score) was calculated by
multiplying the intensity score by the percentage score
(0–300). An H-score higher than the median was consid-
ered positive. Negative controls were incubated without the
primary antibody.
Statistical analysis
Associations between Snail expression and the clinico-
pathological characteristics were analyzed using Fisher’s
exact test. Disease-free survival and disease-specific survival
were calculated using the Kaplan-Meier method, and
differences in survival among groups were compared
using the log-rank test. We used Cox proportional hazards
regression analysis to assess Snail expression and sex for
disease-specific survival. Values of p < 0.05 were considered
significant. All statistical analyses were performed with
Table 1 Clinicopathological factors of bladder cancer and
associations with Snail protein expression
Patients (%) Snail expression
Negative Positive P
All patients 44 29 15
Age 1.00
<70 years 17 (39%) 11 6
≥70 years 27 (61%) 18 9
Sex 0.70
Male 36 (82%) 23 13
Female 8 (18%) 6 2
Pathological T stage 0.47
1 14 (32%) 11 3
2a 20 (45%) 12 8
2b 10 (23%) 6 4
Histological grade 0.54
Low 3 (7%) 3 0
High 41 (93%) 26 15
Concurrent CIS 0.68
Yes 7 (16%) 4 3
No 37 (84%) 25 12
Lymphovascular invasion 1.00
Yes 3 (7%) 2 1
No 41 (93%) 27 14
10
2 3
Figure 1 Sample immunohistochemical images of Snail staining in bladder cancer. Snail expression scores by immunohistochemistry. 0, no
staining; 1, weak; 2, moderate; 3, strong.
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The baseline characteristics of all 44 patients are shown
in Table 1. The mean age of patients at first TURBT was
70 years (range, 43-84 years), and only 8 patients were
females. Of the 44 patients, 14 (32%) showed pT1 high
grade, and 30 (68%) had pT2. Cystectomy was performed
after neoadjuvant chemotherapy in 4 patients (9.1%). With
a median follow-up of 47 months, the 5-year survival rate
was 82.7% for all patients. At the time of analysis, 36
patients (81.8%) remained alive, and 8 patients (18.2%)
had died of bladder cancer. Overall and disease-specific
survivals were thus similar.
Immunohistochemical assessment of snail expression
Snail was localized in the nucleus of bladder tumor
cells. There was no difference in snail staining between
superficial and invasive bladder tumor cells (Figure 2).
Representative cases for the different staining levels (0, 1,
2, 3) are presented in Figure 1. The median H-score was
10 (range, 0-240). Tumors with an H-score > 10 were
deemed Snail positive. Twenty-nine specimens (65.9%)
showed low Snail expression, whereas 15 specimens
showed high expression (34.1%).
The relationships between Snail expression and clinico-
pathological factors are summarized in Table 1. No signifi-
cant association was observed between Snail expression
and the clinicopathological factors of sex, age, pathological
Figure 2 Immunohistochemical staining of Snail in superficial and invasive bladder tumor cells. (A) cells visualized under 40×
magnification. (B) shows superficial bladder tumor cells (100× magnification). (C) shows invasive bladder tumor cells (100× magnification).
Nomura et al. BMC Urology 2013, 13:73 Page 4 of 6
http://www.biomedcentral.com/1471-2490/13/73T stage, histological grade, concurrent CIS or lympho-
vascular (p > 0.05).
Snail expression and survival
Disease-free survival was significantly shorter for Snail-
positive patients than for Snail-negative patients (p = 0.014;
Figure 3A). In addition, disease-specific survival was
significantly shorter for Snail-positive patients than for
Snail-negative patients (p = 0.039; Figure 3B). Snail expres-
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Figure 3 Kaplan-Meier estimates of disease-free survival and disease-
analysis of disease-free survival (A) and disease-specific survival (B) of the T
chemotherapy according to the Snail expression.time only in T2 bladder cancer patients (p < 0.05), not in
T1 high-grade bladder cancer patients (p > 0.05).
Multivariate analysis was performed to evaluate the
influence of Snail on the disease-specific survival adjusting
for possible confounding factors. From the results in
Table 1, there were no clinicopathological factors, which
was significantly correlated to Snail. From the results of
the univariate analysis, Snail and Sex were significantly
correlated to the disease-specific survival. Therefore, only
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specific survival in patients with bladder cancer. Kaplan-Meier
1 high-grade and T2 bladder cancer patients treated with neoadjuvant
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and the HR was 6.39 (95% CI: 1.33-30.6) (Table 2).
Discussion
The present study demonstrated a significant association
between Snail expression and survival in T1 high-grade
and T2 bladder cancer patients treated with neoadjuvant
chemotherapy. A high level of Snail expression was asso-
ciated with decreased disease-free survival and disease-
specific survival time in T1 high-grade and T2 bladder
cancer patients treated with neoadjuvant chemotherapy.
In multivariate analysis, Snail expression levels emerged as
independent prognostic markers of disease-specific survival.
Therefore, Snail expression may predict poor outcome in
T1 high-grade and T2 bladder cancer patients treated with
neoadjuvant chemotherapy.
Snail is considered a key regulator of EMT and, thereby,
of tumor progression and resistance to chemotherapy.
Bruyere et al. reported that Snail expression predicts
tumor recurrence in superficial bladder cancer [17].
Kosaka et al. reported that Snail expression is a prognostic
predictor of disease-free survival and disease-specific
survival in upper urinary tract urothelial carcinoma [18].
Resistance to chemotherapy has not been reported in
bladder cancer. However, Snail expression has been re-
ported to promote resistance to chemotherapy in pancre-
atic and colorectal cancer [19,20]. These findings support
the results of the present study.
Various pathological factors have been reported as prog-
nostic markers for poor survival in patients with bladder
cancer, but they are inadequate for predicting response to
chemotherapy. Thus, molecular markers that may better
predict the efficacy of chemotherapy against such tumors
have been sought. The gene expressions of BRCA1,
MDR1, and ERCC1 were reported to be useful as markers
to predict the efficacy of chemotherapy for bladder cancerTable 2 Univariate and multivariate analysis for disease-free






















0.014 0.039 6.39 (1.33-30.6) 0.020patients [21-23]. However, none of these markers is
presently in clinical use. All examinations had been
performed using reverse transcriptase-polymerase chain
reactions, which require complicated procedures. The
clinical feasibility of carrying out the examination would
be limited. The immunohistochemical analysis used in the
present study can be applied in almost every pathology
laboratory. The present findings could thus be widely
applicable in clinical practice.
The results of this study indicate that Snail could help
identify patients with T1 high-grade and T2 bladder cancer
who would be resistant to neoadjuvant chemotherapy.
A selective approach using this information would result
in patients with high Snail expression undergoing radical
cystectomy. Thus, delayed cystectomy because of neo-
adjuvant chemotherapy could be avoided. However, pa-
tients with low Snail expression would receive neoadjuvant
chemotherapy. Prospective studies applying this kind of
approach are needed in the future.
Only in T2 bladder cancer patients was Snail expression
associated with decreased disease-specific survival time;
no significant association was observed between Snail
expression and disease-specific survival time in T1 high-
grade bladder cancer patients. Since Snail positivity was
quite low (3 out of 14 cases) in T1 high-grade bladder
cancer, further studies with a large number of patients are
warranted to confirm this result.
The present results suggest that determination of Snail
expression may predict survival in T1 high-grade and T2
bladder cancer patients treated with neoadjuvant chemo-
therapy. However, this study had quite a small sample size
and was a retrospective analysis. Thus, a prospective study
with a large cohort is needed to confirm our preliminary
results.
Conclusions
The results from this study indicate that Snail might
represent a novel molecular marker for predicting poor
outcome in T1 high-grade and T2 bladder cancer patients
treated with neoadjuvant chemotherapy.
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